Prognostic value of p27(Kip1 )expression in Basaloid Squamous Cell Carcinoma of the larynx by Salerno, Grazia et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Prognostic value of p27Kip1 expression in Basaloid Squamous Cell 
Carcinoma of the larynx
Grazia Salerno*†1, Dolores Di Vizio†2, Stefania Staibano2, 
Giampiero Mottola1, Giuseppe Quaremba3, Massimo Mascolo2, Vieri Galli1, 
Gaetano De Rosa2 and Luigi Insabato2
Address: 1Department of Otolaryngology, University Federico II, Naples, Italy, 2Department of Biomorphologic and Functional Sciences, 
Pathology Section, University Federico II, Naples, Italy and 3Department of Mechanical Engineering for Energetic, University Federico II, Naples, 
Italy
Email: Grazia Salerno* - grazia.salerno@tin.it; Dolores Di Vizio - Dolores.DiVizio@chidrens.harvard.edu; 
Stefania Staibano - staibano@unina.it; Giampiero Mottola - giampieromottola@hotmail.com; Giuseppe Quaremba - quaremba@unina.it; 
Massimo Mascolo - mmascol@libero.it; Vieri Galli - vieri.galli@unina.it; Gaetano De Rosa - gaderosa@unina.it; 
Luigi Insabato - insabato@unina.it
* Corresponding author    †Equal contributors
Abstract
Background: Very few reports have investigated the role of cell cycle regulators as biomarkers in Basaloid Squamous
Cell Carcinoma (BSCC) of the larynx, a definite morphologic, uncommon, very aggressive variant of squamous cell
carcinoma. Lower expression of Ki67/Mib-1, a proliferation marker highly expressed in the majority of tumours, and p53,
a tumour suppressor protein that can induce an arrest of the G1-S transition, was related to a better prognosis in
laryngeal BSCC. In the head and neck, p27kip1, a member of the Cip1/Kip1 family of cyclin-dependent kinase inhibitors,
has emerged as an independent prognostic factor, able to identify low-expressing tumours with unfavourable course. Up
to date the role of this protein was never studied in BSCC. Aim of our study was to investigate the potential prognostic
value of p27kip1 levels and their correlation with Ki67/Mib-1 and p53 expression in BSCC of the larynx.
Methods: The retrospective study group consisted of 15 male and 1 female patients, affected by laryngeal BSCC, ranging
in age from 44 to 69 years (mean 58). The tumour originated from the supraglottis in thirtheen cases and from the glottis
in the remaining three. Ten patients had metastatic cervical lymph nodes at presentation and were classified as N+. Post
surgical stage was IV in four patients, III in nine, II in two cases and I in the remaining one. Follow-up ranged from a
minimum of 5 months up to 9 years. Paraffin-embedded tissue sections of each laryngeal tumour were analyzed for p27kip,
Ki67/Mib-1 and p53 expression by immunohistochemistry.
Results: The immunohistochemical study showed p27kip1 expression in 40% of the patients with no evidence of disease
(NED) and in none (0%) of the patients dead of disease (DOD), whilst p53 was expressed in 60% of patients in NED
status and in 90% of patients in DOD status. Ki67/Mib-1 was positive in 80% of NED patients and in 100% of DOD
patients. At multivariate analysis, performed by means of Discriminant analysis, low levels of p27kip1 expression
significantly correlated with poor prognosis (P < 0.05).
Conclusion: p27kip1 protein has been shown to be a significant independent prognostic factor in laryngeal SCC. In our
series of laryngeal BSCC the resulting data seem to confirm the clinical prognostic relevance of p27kip1 low expression,
which directly correlated with biological aggressiveness and consequent shortened survival.
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Background
Basaloid squamous cell carcinoma (BSCC) is a definite
morphologic, uncommon, very aggressive variant of squa-
mous cell carcinoma (SCC), which is predominantly
localized in the upper aero-digestive tract. In the head and
neck region, this distinctive tumour has a strong predilec-
tion for extra-laryngeal sites, such as the base of the
tongue, the hypopharynx and the supraglottic larynx.
This neoplasm shows a predominant basaloid pattern of
growth intimately associated to areas of squamous cell
carcinoma and/or adjacent regions of severe dysplasia and
carcinoma in situ. It mainly affects men in the sixth and
seventh decades of life and usually presents at diagnosis in
advanced stages, with positive lymph nodes and/or dis-
tant metastases.
Since the first cases described by Wain et al [1] in 1986 a
few hundreds of cases of BSCC of the aero-digestive tract,
head and neck have been reported [2-24]; among them,
about 70 cases are from larynx. It is a very rare variant of
Squamous Cell Carcinoma (SCC) in this site and to our
knowledge, only few isolated cases and very small series
were described, with a maximum of 11 reported cases per
series. The morphological features are sufficient to diag-
nose this tumour.
Recently various cell cycle regulators were investigated as
biological markers of malignant potential, in an attempt
to select which one might influence outcome and the
effects of adjuvant therapies. Although conflicting data
have emerged regarding the tumorigenesis and the clinical
implications of cell cycle regulators in laryngeal SCC, p53
accumulation and Cyclin D1 over-expression have been
consistently associated with poor prognosis [25]. The cyc-
lin-dependent kinase inhibitor p27kip1is recognized as a
negative regulator of the cell-cycle, since it blocks progres-
sion from the G1 to the S phase by binding cyclin E-CDK2
and inhibiting their activities. Reduced expression of
p27kip1is related to progression in precancerous laryngeal
lesions [26] and to cell proliferation and poor prognosis
in laryngeal squamous cell carcinoma [27-33].
Few reports have investigated the use of cell cycle regula-
tors as prognostic factors in BSCC of the larynx. Ki67/Mib-
1 and P53 status were examined in two small series of
BSCC of the larynx, resulting in absence of significant cor-
relation of their levels with the clinical findings [34,35].
Recently, Marioni et al [21] investigated the expression of
endoglin (CD105), a useful marker for identifying prolif-
erating endothelium involved in tumour angiogenesis, in
head and neck BSCCs and SCCs. They did not find any sig-
nificant differences between the two groups. Rodriguez
Tojo et al [22] retrospectively studied the immunoexpres-
sion of p53, Ki67/Mib-1 and E-cadherin in 11 cases of
laryngeal BSCC, showing that the lower expression of
Ki67/Mib-1 and p53 was related to the better prognosis
and in all the cases E-cadherin was down regulated.
This study adds 16 new cases of BSCC of the larynx and
investigates the expression and the potential prognostic
role of cell cycle regulator p27kip1 together with its correla-
tion with Ki67/Mib-1 and p53 expression in BSCC of the
larynx.
Methods
Selection of cases
From the archival files of the Department of Biomorpho-
logic and Functional Sciences, Pathology Section of the
University "Federico II" of Naples, 16 cases of BSCC of the
larynx were selected from January 1987 to December
2000 by a review of all laryngo-hypopharyngeal cancers
reported. Only tumours showing a prominent basaloid
pattern were included in the study. For each case, Hema-
toxylin-Eosin stain sections confirmed the original diag-
nosis. All cases fulfilled the basic histological features of
BSCC [1].
The clinical records of the patients, i.e., site, TNM status,
treatment and follow-up data (length of time since sur-
gery and disease-free interval time to recurrence or death
from surgery) are reported in Table 1.
Our series of BSCC consisted of 15 men and 1 woman,
whose age at diagnosis ranged from 44 to 69 years (mean
age 58). All patients were heavy smokers, with smoking
histories ranging from 10 to 30 packets/month. Symp-
toms at presentation were hoarseness, throat discomfort
and dysphagia. Bleeding was an associate symptom in two
cases only. The tumour originated from the supraglottis in
13 patients and from the glottis in the remaining three
ones; ten patients were N+ at presentation (62.5%) and
none of the patients had distant metastasis at the first
examination. Post surgical stage was IV in four patients
(25%), III in 9 cases (56.2%), II in 2 cases (12.5%) and I
in the remaining patient (6.3%). Follow-up ranged from
a minimum of 5 months to 9 years.
The primary neoplasm and all regional lymph nodes were
surgically excised in 14 cases by either a total laryngec-
tomy or supraglottic laryngectomy, depending on the size
and location of the tumour; laser surgery was the preferred
surgical approach in the remaining two patients. Eleven
patients (68.7%) received postoperative radiotherapy
Ethical board and informed consent
The Italian law, with reference to the present research,
does not provide for the Ethical Committee approval (see
"Circolare del Ministero della Salute" no. 6 dated September
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Following the indication of Italian DLgs no. 196/03
(Codex on Privacy) a written consent was obtained from
the alive patients.
Immunohistochemistry
4 μm sections for each case were pre-incubated in a micro-
wave oven for 15 minutes in 10 mmol/L, 6.0 pH buffered
citrate followed by the immunohistochemical procedure
for Ki67/Mib-1, p53, and p27kip1. Ki67/Mib-1 (DAKO)
diluted 1:50; p53 (BIOGENEX, San Ramon, CA,) diluted
1:300; p27kip1 monoclonal antibody (Transduction Labo-
ratories, Lexington, KY) diluted 1:500. The conventional
avidin-biotin complex procedure was applied according
to the manufacturer protocol and the nuclei were counter-
stained with Mayer's hematoxilin and cover slipped with
a synthetic, xylene based, mounting medium. Five differ-
ent high magnification fields of represented areas of
tumours were evaluated.
For each antibody only the neoplastic cells showing a def-
inite nuclear staining were considered as positive and a
semi quantitative evaluation was performed. High expres-
sion of p27kip1, p53 and Ki67/Mib-1 proteins was defined
when >50%, >10%, and >10% of cell nuclei were positive,
respectively; 0 and 1 were used to discriminate between
low and high expressing tumours [36][37]. Two observ-
ers, blinded to the follow-up data of single cases, inde-
pendently evaluated the results. As internal control for
p27kip1 immunostaining, resting lymphocytes were used.
Statistical analysis
Discriminant analysis with a stepwise elimination of vari-
ables was performed to build up a predictive model of
group membership based on observed characteristics of
each case [38]. The model included the following varia-
bles as risk factors: age, tumour site, nodal status at pres-
entation, adjuvant radiotherapy, p27kip1, p53 and Ki67/
Mib-1 expression. In the statistical evaluation, the level of
significance used was P < 0.05. The Wilks' lambda method
was used for selecting the test set to assess the success of
the discriminant function and for choosing the discrimi-
nant variables [39].
The Box's Test of Equality of Covariance Matrices was per-
formed to test the assumption that the population under
study had a multivariate normal distribution and equal
variance-covariance matrices. The amount of explained
variance was calculated by co linearity diagnostics and
multivariate methods [40]. Finally, the sample was
divided in two groups depending on the outcome:
patients dead of disease (DOD) and patients with no evi-
dence of disease (NED).
The whole analysis were performed by means of statistical
software for Windows (SPSS 10.0, Chicago, III)
Results
Ten patients (62.5%) died of disease (DOD) despite of
salvage surgery and radiotherapy: among them, seven
(63.6%) died in the first five years after surgery. Four
patients (25%) have no evidence of disease (NED) actu-
ally. One patient (6.3%) had a successful treatment for a
neck recurrence occurring in the first year after primary
surgery and he was disease-free after 9 years. One patient
(6.3%) is alive with disease (AWD), i.e. a neck recurrence
Table 1: Follow-up of 16 cases of BSCC of the larynx
Case Age Sex Site of origin Staging Treatment Follow-up Remarks
1 44 M SG T3N1M0 TL, FND, RT DOD 7 yrs LR
2 54 M SG T3N0M0 SL, FND DOD 6 yrs Lung M
3 57 M SG T2N0M0 Laser NED > 9 yrs NR after 9 m, ND
4 51 M G T3N2M0 TL, FND, RT NED > 8 yrs
5 55 M G T3N1M0 TL, FND, RT DOD 7 yrs NR, LR
6 64 M SG T4N0M0 SL, FND, RT DOD 4 yrs NR, LR
7 63 M SG T2N0M0 SL, FND NED > 7 yrs
8 46 M SG T3N1M0 TL, FND, RT AWD >7 yrs NR after 3 yrs
9 51 M SG T3N1M0 TL, FND, RT DOD 2 yrs LR
10 67 M SG T2N1M0 SL, FND, RT DOD 5 yrs LR
11 63 M SG T3N1M0 TL, FND, RT DOD 4 yrs NR, LR
12 51 M SG T4N2M0 SL, FND, RT DOD 3m Lung an Liver M
13 69 M G T1N0M0 Laser NED > 6 yrs
14 64 M SG T4N2M0 TL, FND, RT NED > 6 yrs
15 54 F SG T4N2M0 TL, FND, RT DOD 4 yrs NR, Lung M
16 69 M SG T3N0M0 TL, FND DOD > 2 yrs NR, LR
SG = Supraglottic, G = Glottic, SL = supraglottic laryngectomy; FND = functional neck dissection; RT = radiotherapy; TL = total laryngectomy; 
DOD = dead of disease; NED = no evidence of disease; AWD = alive with disease; NR = neck recurrence; LR = local recurrence; M = distant 
metastases; SNS = salvage neck surgery.BMC Cancer 2006, 6:146 http://www.biomedcentral.com/1471-2407/6/146
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occurred 4 years after the primary surgery, that was treated
with associate radio- and chemotherapy.
Histologically, in nine cases (56.3%) the lesions were
composed of basaloid cell nests showing an irregular lob-
ular pattern of growth with a focal squamous differentia-
tion; a small amount of squamous cell carcinoma was
focally seen (Fig. 1A–B). The amount of squamous cell
carcinoma was more conspicuous in the remaining seven
cases (43.7%) that showed a combination of basaloid and
squamous areas differently intermixed to each other, the
basaloid component being widely prominent. The neo-
plastic cells had a typical scant cytoplasm, with round to
oval, hyperchromatic or, occasionally, large and vesicular
nuclei without prominent nucleoli. Mitotic figures and
nuclear pleomorphism were frequently observed in all
cases. Some basaloid nests displayed central necrosis
without keratinization, whereas the cells at the invading
front of the tumour tended to show peripheral nuclear
palisade arrangements. Areas of hyalinization were
present.
There was no variability in the pattern of staining among
the samples and the discrepancy between the two observ-
ers was negligible. Intratumoural variability was not
present. Raw data with median % score and range for each
antibody and each case are reported in Table 2.
The immunohistochemical study showed that p27kip1 was
highly expressed in 40% of the NED patients and, strik-
ingly, in none (0%) of the DOD patients, whilst p53 and
Ki67 were highly expressed respectively in 60% and 80%
of the patients in NED status and in 90% and 100% of the
patients in DOD status (Table 3). At multivariate analysis
Basaloid nests displaying central necrosis without keratinization Figure 1
A Basaloid nests displaying central necrosis without keratinization. B Basaloid cell nests showing an irregular lobular pattern of 
growth with a focal squamous differentiation (arrow). C Immunohistochemical stain with Ki-67/Mib1 showing strongly positive 
tumour cells at the periphery of the nest. D Basaloid nest showing p27kip1 positive staining tumour cells toward the central of 
the nest, whereas the cells at the invading front of the tumour are negative.  E p27kip1 positive staining in the areas of squa-
mous cell differentiation.
AB
C D
B
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high p27kip1 expression demonstrated to be significant (p
= 0,01). No significant inverse correlation was found
between p27kip1 expression and p53 or to Ki67/Mib-1
expression in DOD and NED patients groups. When the
clinical series was globally evaluated, a slight trend for
inverse correlation (P = -0,33 for p53 and P = -0.447 for
Ki67/Mib-1) resulted.
Interestingly Ki67 staining showed an intense signal in the
tumour cells at the periphery of the nests (Fig. 1C), while
the internal cell counterpart, facing the degenerating,
necrotic centre of the tumour nests, occasionally showed
positive tumour cells. In an inverse manner, p27kip1 stain-
ing, when present, was specifically polarized, highlighting
the cells toward the central necrosis, whereas the basal
Table 2: p27kip1, p53 and Ki67/Mib-1 antibodies range and median % score
Case Field 1 Field 2 Field 3 Field 4 Field 5 Median % score and
1 10* 15* 10* 13* 15* 13* (10/15)
20° 20° 18° 16° 16° 18° (16/20)
30# 30# 32# 28# 30# 30# (28/32)
2 20* 18 20* 18* 20* 20* (18/20)
31° 30° 27° 28° 30° 30°/27/31)
28# 26# 24# 28# 30# 28# (24/30)
3 15* 18* 18* 17* 20* 18* (15/20)
25° 30° 28° 27° 29° 28° (25/30)
28# 26# 24# 28# 30# 28# (24/30)
4 50* 52* 54* 60* 55* 54* (50/60)
15° 17° 16° 14° 17° 16° (14/17)
25# 20# 22# 24# 25# 24# (20/25)
5 5 *7 *7 *5 *4 *5 *  ( 4 / 7 )
25° 28° 27° 30° 25° 27° (25/30)
30# 31# 35# 28# 30# 30# (28–35)
6 16* 20* 18* 15* 16* 16* (15/20)
18° 12° 12° 13° 14° 13° (13/18)
25# 20# 22# 24# 25# 24# (20/25)
7 15* 14* 15* 20* 18* 15* (14/20)
5° 4° 4° 5° 3° 4° (3–5)
20# 21# 22# 20# 25# 21# (20/25)
8 52* 54* 55* 58* 60* 55* (52/60)
2° 2° 4° 3° 3° 3° (2/3)
30# 29# 32# 20# 31# 30# (20/31)
9 4 *6 *7 *8 *8 *7 *  ( 4 / 8 )
7° 6° 5° 8° 6° 6° (5/8)
38# 34# 33# 30# 37# 34# (30/38)
10 20* 18* 20* 22* 20* 20* (18/22)
12° 14° 18° 10° 20° 14° (10/20)
30# 32# 28# 28# 35# 30# (28/35)
11 15* 17* 16* 18* 20* 17* (15/20)
20° 21° 20° 18° 24° 20° (20/24)
28# 35# 30# 35# 30# 30# (28/35)
12 20* 22* 20* 18* 20* 20* (18/22)
27° 26° 24° 24° 27° 26° (24/27)
30# 30# 26# 26# 28# 28# (26/30)
13 54* 50* 58* 54* 50* 54* (50/58)
5° 5° 4° 7° 6° 5° (4/7)
8# 7# 7# 5# 8# 7# (5/8)
14 4* 6* 8* 6* 8* 6* (4/8)
15° 15° 12° 13° 14° 14° (12/15)
25# 24# 22# 25# 24# 24# (22/25)
15 10* 10* 12* 18* 12* 12* (10/18)
23° 22° 20° 22° 20° 22° (20/23)
35 34# 34# 30# 34# 34# (30/35)
16 15* 17* 18* 16* 15* 16* (15/18)
30° 28° 30° 32° 28° 30° (28/32)
40# 38# 35# 35# 30# 35# (30/40)
(*) p27kip1 (°) p53 (#) ki/67 Mib-1BMC Cancer 2006, 6:146 http://www.biomedcentral.com/1471-2407/6/146
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cells at the invading front of the tumour, showing periph-
eral nuclear palisading arrangements, were negative (Fig.
1D). p27kip1  positive staining was characteristically
revealed mainly in the areas of squamous cell carcinoma
(Fig. 1E).
Backward elimination of variables by stepwise procedure
(at each step, removing the variable that contributes least
to group discrimination) isolated the variable p27kip1 (P =
0.01). The 81,3% of subjects were correctly well classified
as belonging to the group membership (Tabs 4, 5).
Discussion
Although Squamous Cell Carcinoma (SCC) represents the
majority of laryngeal cancers, new entities with more
severe prognostic implications have been described. One
of them is Basaloid Squamous Cell Carcinoma (BSCC),
first reported as a clinical-pathologic entity by Wain et al
in 1986 [1]. This rare tumour is a histological distinctive
variant of SCC with predilection for head and neck region,
generally presenting in advanced stage at diagnosis, char-
acterized by aggressive clinical course and extremely poor
prognosis.
The survival of patients with head and neck cancer has not
changed in the last thirty years [40-42]. The progresses of
the classical therapeutic strategies, such as irradiation and
surgery, have been unsuccessful in improving the survival
rate for these patients. Clinical general status, histopathol-
ogy examination and tumour classification still remarka-
bly influence the treatment plan.
Several prognostic criteria have been hypothesized to play
a role in SCC outcome in the past two decades. Some of
the traditional parameters (TNM classification) have been
considered useful in predicting the clinical behaviour of
this tumour. Nevertheless, the need of finding more relia-
ble predictors of the biological behaviour in single case
has become mandatory, with the resultant recent studies
on the role of oncogenic markers in tumour onset and
progression of SCC [30,44-46]
To the best of our knowledge only four studies investigat-
ing the role of oncogenic markers in laryngeal BSCC have
been published [21,22,34,35]. In our study the prognostic
value of Ki67/Mib-1, p53 and p27kip1 proteins immu-
Table 3: Immunohistochemical expression of p27kip1, p53 and 
Ki67/Mib-1
Case p27kip1 p53 Ki67 Outcome
1011D O D
2011D O D
3011N E D
4111N E D
5011D O D
6011D O D
7001N E D
8101A W D
9001D O D
1 0 011D O D
1 1 011D O D
1 2 011D O D
1 3 100N E D
1 4 011N E D
1 5 011D O D
1 6 011D O D
(*) p27kip1 (°) p53 (#) ki/67 Mib-1
Table 4: Multivariate analysis
Step Tolerance Min. Tolerance F to Enter Wilks' Lambda
0 age 1.000 1.000 .070 .995
size 1.000 1.000 2.827 .832
n 1.000 1.000 .583 .960
radio 1.000 1.000 .583 .960
p27 1.000 1.000 8.750 .615
ki67 1.000 1.000 1.750 .889
p53 1.000 1.000 3.500 .800
1 age .944 .944 .561 .590
size .982 .982 .955 .573
n .954 .954 1.175 .564
radio .954 .954 1.175 .564
ki67 .800 .800 .000 .615
p53 .931 .931 .731 .583
Test of Function(s) Wilks' Lambda Chi-square df Sig.
1 .615 6.554 1 .010BMC Cancer 2006, 6:146 http://www.biomedcentral.com/1471-2407/6/146
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noexpression was analyzed in 16 cases of BSCC of the lar-
ynx.
Ki67/Mib-1 is a proliferation marker highly expressed in
the majority of tumours [47-49]. The Ki67/Mib-1 prolifer-
ation index, however, does not allow an unequivocal dis-
crimination between cancers with different "biological"
behaviour. Moreover, the data on the relationship
between p53 and Ki67 expression, obtained in different
tumour types and from different series are somehow con-
troversial.
p53 and p27kip1 play a pivotal role in regulating the cell
cycle. p53 is a nuclear phosphoprotein inhibiting cell
cycle progression and inducing apoptosis, both regulated
by several target genes. It ultimately functions as a tumour
suppressor gene, which can induce, in response to
mitogenic stimuli, an arrest of the G1-S transition. p53
mutations are extremely frequent in human cancers, and
missense p53 mutations with consequent over-expression
of a dysfunctional but otherwise intact protein have been
described [46]. In head and neck cancer, data from litera-
ture show conflicting evidence concerning the correlation
between p53 expression and the most common clinico-
pathological parameters [36,45,49-51]. Recently p53
expression, together with Cyclin D1 over-expression, has
been associated with reduced survival in laryngeal SCC
[25].
p27kip1 plays an important role in protecting cells from an
exuberant proliferation, by regulating cyclin dependent
kinase activity thus inhibiting the G1-S transition [52]. Its
function results inactive in several human tumours, either
by degradation via the SCF-type E3 ubiquitin ligase, Skp2
[53] or by sequestration through Cyclin D3 [54]. In the
head and neck cancer, p27kip1 expression has been consid-
ered as an independent prognostic factor, able to correlate
low-expressing tumours with unfavourable course. Jordan
et al. [55] demonstrated that p27kip1 was significantly
reduced in oral dysplasia and carcinomas, while it was
retained in normal epithelial controls. Interestingly,
p27kip1 levels displayed a significant reduction in high
grade in comparison with low grade dysplasia, suggesting
that changes in p27kip1 expression may be an early event
in oral carcinogenesis. In the larynx, a reduced expression
of p27kip1protein correlates with progression in precancer-
ous lesions [26] and with an aggressive biological behav-
iour in laryngeal SCC [30]. According to Pruneri et al [27]
and Pignataro et al [33], immunohistochemical evalua-
tion of p27kip1 expression is a significant independent pre-
dictor of prognosis in laryngeal carcinoma, as previously
stated by Fan et al. [28] who found p27kip1 expression to
be the most powerful prognostic factor among gender,
tumour size, lymph node metastasis, stage of disease and
p53 expression. Up to now, the role of p27kip1 as prognos-
ticator has never been investigated in BSCC of the larynx.
In our series, p27kip1 immunohistochemical levels were
nearly abolished in all DOD patients, and highly
expressed in a large fraction of the patients with NED. p53
and Ki67 were globally highly expressed both in the
patients with NED and in the DOD group, with a slightly
lower expression in the former samples compared to the
DOD patients. The correlation between p27kip1 expression
and p53 or to Ki67/Mib-1 expression in DOD and NED
patients groups was not statistically significant although
there was a trend suggesting that it was inverse. The find-
ing that both KI67 and p53 are over-expressed in a rele-
vant fraction of our patients exhibiting poor outcome is in
agreement with numerous published studies attributing
to the above proteins a role as predictors of adverse prog-
nosis in several human tumour types, including head and
neck cancers. Never less, Ki67 and p53 expression were
widely and abundantly retained also in patients in NED
status, and were not able to discriminate, in a significant
manner, between different outcomes. The result is not sur-
Table 5: Multivariate analysis
Variables Entered/Removeda, b, c, d
Wilks' Lambda
Exact F
Step Entered Statistic df1 df2 df3 Statistic df1 df2 Sig.
1 p27 .615 1 1 14.000 8.750 1 14.000 .010
At each step, the variable that minimizes the overall Wilks' Lambda is entered.
a. Maximum number of steps is 16.
b. Minimum partial F to enter is 3.84.
c. Maximum partial F to remove is 2.71.
d. F level, tolerance, or VIN insufficient for further computation.BMC Cancer 2006, 6:146 http://www.biomedcentral.com/1471-2407/6/146
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prising in itself, considering the high proliferative capabil-
ity and potential of aggressiveness of BSCC when
compared to different histotypes.
Another interesting consideration comes out from the
observation that p27kip1 expression is mainly localized in
the focal areas of squamous cell carcinoma, supporting its
role in cell differentiation. We did not find any associa-
tion between squamous component representation and
prognosis. In addition p27 expression, as well as the
expression of Ki67 and p53, was exclusively evaluated in
the pure basaloid areas.
The basaloid nests showed a p27kip1 positivity that, when
present, was specifically polarized and located in the cells
toward the central necrosis, some of which with a squa-
mous-like appearance, whilst the cells at the invading
front of the tumour, showing peripheral nuclear palisad-
ing arrangements, were negative for p27kip1 and intensely
positive for p53, and Ki67/Mib-1.
To conclude, this study about cell cycle regulators involve-
ment in BSCC of the larynx seems to confirm published
data showing a direct correlation between decreased
expression of p27kip1and poor prognosis in SCC of the
head and neck. Multivariated analysis suggested a clinical
prognostic relevance of p27kip1  low expression, which
directly correlated with biological aggressiveness and con-
sequent shortened survival. Further studies on larger series
of BSCC warrant to better clarify this relationship.
The assessment of p27kip1 expression seems very useful to
select patients for more aggressive therapies and to estab-
lish which cases can benefit from cell cycle inhibitor suit-
able drugs candidates [56] (i.e. the epidermal growth
factor receptor tyrosine kinase inhibitor ZD1839 [57] and
the cyclin-dependent kinase modulator UCN-01 (7-
hydroxy-staurosporine) [58] or from new cancer gene
therapy [59,60].
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